SCHEMBL14683530

SCHEMBL14683530

C[C@@H]1C(OC(=O)c2ccccc2)[C@H](OCc2ccccc2)OC(COC(=O)c2ccccc2)[C@H]1O[C@@H]1OC(CO)[C@H](O)[C@H](C)C1OC(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 3/20 0.45
▸ LGALS9 O00182 2/20 0.45
▸ LGALS1 P09382 2/20 0.45
▸ LGALS7; LGALS7B P47929 2/20 0.45
▸ LGALS8 O00214 1/20 0.44
▸ SELP P16109 8/20 0.42
▸ FGF1 P05230 2/20 0.42
▸ FGF2 P09038 2/20 0.42
▸ VEGFA P15692 2/20 0.42
▸ HPSE Q9Y251 2/20 0.42
▸ NT5E P21589 1/20 0.41
▸ SELE P16581 2/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ LGALS4 P56470 1/20 0.39
▸ TYMP P19971 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19249303 0.88 LGALS3 (0.49) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL15952812 0.87 LGALS3 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL15952811 0.87 LGALS3 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL15965619 0.87 TYMP (0.40) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL15965621 0.86 LGALS3 (0.45) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL14683528 0.85 FGF1 (0.43) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL18925422 0.84 LGALS3 (0.50) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL12920535 0.84 NT5E (0.54) FGF1FGF2VEGFAHPSENT5E
SCHEMBL3700974 0.83 ANTXR2 (0.50) FGF1FGF2VEGFAHPSENT5E
SCHEMBL4402910 0.83 FGF2 (0.41) SELPFGF1FGF2VEGFAHPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9237764-B2 Production of 6′-O-sialyllactose and intermediates GLYCOM A/S (DK) 2016-01-19 — — US disclosed
US-20140057868-A1 CATALYTIC HYDROGENOLYSIS OF A COMPOSITION OF A MIXTURE OF OLIGOSACCHARIDE PRECURSORS AND USES THEREOF GLYCOM A/S (DK) 2014-02-27 — — US disclosed
US-20140046044-A1 NOVEL GLYCOSYL PHOSPHITES GLYCOM A/S (DK) 2014-02-13 — — US disclosed
US-20130035481-A1 PRODUCTION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATES GLYCOM A/S (DK) 2013-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057868-A1 CATALYTIC HYDROGENOLYSIS OF A COMPOSITION OF A MIXTURE OF OLIGOSACCHARIDE PRECURSORS AND USES THEREOF MGAM, SI, GALK1 LGALS3 792/4885LGALS9 619/4885LGALS1 449/4885
US-20130035481-A1 PRODUCTION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATES ST6GAL1, FUT6, FUT5 LGALS3 354/4885LGALS9 207/4885LGALS1 293/4885
US-20140046044-A1 NOVEL GLYCOSYL PHOSPHITES GPI, FUT5, UGGT1 LGALS3 406/4885LGALS9 287/4885LGALS1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback